February 22, 2024Open Access

FIGURE 4 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies

Key Points

Key points are not available for this paper at this time.

Abstract

Effect of BMS-986351, alone or in combination with rituximab, on the proportion of phagocytic macrophages in ABC (A) and GCB (B) cell lines. ABC, activated B cell; GCB, germinal center B cell.

FIGURE 4 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies

Key Points

Abstract

Cite This Study